BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Core Insights - BriaCell Therapeutics Corp. is expanding its pivotal Phase 3 clinical study by adding major cancer centers, which is expected to enhance patient enrollment and support the development of its immunotherapy, Bria-IMT [1][4][10] - The study is focused on advanced metastatic breast cancer, comparing Bria-IMT combined with an immune checkpoint inhibitor against physician's choice of treatment [3][5] - The company anticipates reporting top-line data as early as the first half of 2026, with interim data analysis planned after 144 patient events [1][6] Company Overview - BriaCell is a clinical-stage biotechnology company dedicated to developing novel immunotherapies aimed at transforming cancer care [8] - The company has received FDA Fast Track designation for the Bria-IMT combination regimen, which could lead to full approval and marketing authorization if positive results are achieved [6] Clinical Study Details - The pivotal Phase 3 study is currently enrolling patients at 79 clinical sites across 23 US states, with the addition of Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University [10] - The primary endpoint of the study is overall survival (OS) in patients treated with the Bria-IMT regimen compared to those receiving physician's choice treatment [6]